Upgrade to SI Premium - Free Trial

Iovance Biotherapeutics (IOVA)

14.81 -0.05 (0.34%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 October 19, 2026 7:00 AM - StreetInsider Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) October 16, 2026 5:15 PM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $18 at Barclays October 13, 2026 3:35 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $11 at Baird October 8, 2026 7:24 AM - StreetInsider Form 8-K IOVANCE BIOTHERAPEUTICS, For: Oct 05 October 5, 2026 5:01 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Sep 30 Filed by: Berkowitz Noah October 2, 2026 5:01 PM - SEC Filing Form 3 IOVANCE BIOTHERAPEUTICS, For: Sep 30 Filed by: Berkowitz Noah October 2, 2026 5:00 PM - SEC Filing Iovance names Noah Berkowitz as chief medical officer October 1, 2026 7:00 AM - StreetInsider Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer October 1, 2026 7:00 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $18 at Wells Fargo September 30, 2026 6:09 AM - StreetInsider High-Stakes October has these Biotechs Entering Crucial Stretch September 29, 2026 12:13 PM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $16 at TD Cowen Following Raised Outlook September 29, 2026 10:00 AM - StreetInsider Iovance shares jump in premarket as raised outlook clears consensus views September 29, 2026 9:11 AM - StreetInsider Form 8-K IOVANCE BIOTHERAPEUTICS, For: Sep 29 September 29, 2026 7:05 AM - SEC Filing Iovance raises 2026 revenue guidance to $410M-$420M September 29, 2026 7:02 AM - StreetInsider Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million September 29, 2026 7:00 AM - StreetInsider Goldman Sachs Assumes Iovanace Biotherapeutics (IOVA) at Buy September 24, 2026 4:59 AM - StreetInsider Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) September 18, 2026 5:10 PM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $15 at Barclays September 17, 2026 4:35 AM - StreetInsider Form 4 IOVANCE BIOTHERAPEUTICS, For: Sep 08 Filed by: Vogt Frederick G September 10, 2026 5:01 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Sep 08 Filed by: BILINSKY IGOR September 10, 2026 5:01 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Sep 08 Filed by: Puri Raj K. September 10, 2026 5:00 PM - SEC Filing Iovance Biotherapeutics to Present at Upcoming Conferences September 4, 2026 8:00 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $10 at TD Cowen August 25, 2026 7:38 AM - StreetInsider TD Cowen Assumes Iovanace Biotherapeutics (IOVA) at Buy August 22, 2026 7:55 AM - StreetInsider Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) August 21, 2026 5:15 PM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $7 at UBS August 20, 2026 6:03 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $11 at Mizuho August 18, 2026 6:36 AM - StreetInsider Form 4 IOVANCE BIOTHERAPEUTICS, For: Aug 10 Filed by: Kirby Daniel Gordon August 12, 2026 5:30 PM - SEC Filing Form 4 IOVANCE BIOTHERAPEUTICS, For: Aug 06 Filed by: Roche Corleen M. August 10, 2026 5:30 PM - SEC Filing Form SCHEDULE 13G IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP August 7, 2026 9:57 AM - SEC Filing Iovanace Biotherapeutics (IOVA) PT Raised to $8 at Citizens August 7, 2026 8:13 AM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $13 at Barclays August 7, 2026 4:54 AM - StreetInsider Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 06 August 6, 2026 5:31 PM - SEC Filing Why Investors Are Watching These Healthcare Movers August 6, 2026 12:32 PM - StreetInsider Iovanace Biotherapeutics (IOVA) PT Raised to $7 at TD Cowen August 6, 2026 10:58 AM - StreetInsider Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Jun 30 August 6, 2026 9:16 AM - SEC Filing Iovance Biotherapeutics (IOVA) Tops Q2 EPS by 2c August 6, 2026 7:32 AM - StreetInsider Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 06 August 6, 2026 7:05 AM - SEC Filing Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates August 6, 2026 7:01 AM - StreetInsider Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 July 30, 2026 8:00 AM - StreetInsider Form SCHEDULE 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: BlackRock, Inc. July 28, 2026 4:47 PM - SEC Filing Full Article List